Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PROCEPT BioRobotics (PRCT) EBITDA (2020 - 2025)

PROCEPT BioRobotics (PRCT) has disclosed EBITDA for 6 consecutive years, with -$29.8 million as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA fell 59.42% to -$29.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$95.6 million, a 4.67% decrease, with the full-year FY2025 number at -$95.6 million, down 4.67% from a year prior.
  • EBITDA was -$29.8 million for Q4 2025 at PROCEPT BioRobotics, down from -$21.2 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$12.8 million in Q1 2021 to a low of -$29.8 million in Q4 2025.
  • A 5-year average of -$22.0 million and a median of -$21.8 million in 2022 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: tumbled 65.64% in 2023, then skyrocketed 31.7% in 2024.
  • PROCEPT BioRobotics' EBITDA stood at -$18.4 million in 2021, then plummeted by 54.65% to -$28.4 million in 2022, then grew by 3.45% to -$27.4 million in 2023, then soared by 31.7% to -$18.7 million in 2024, then tumbled by 59.42% to -$29.8 million in 2025.
  • Per Business Quant, the three most recent readings for PRCT's EBITDA are -$29.8 million (Q4 2025), -$21.2 million (Q3 2025), and -$19.9 million (Q2 2025).